Sign inJoin waitlistJoin the waitlist

Raed Al Rajabi

Co-Chair, 2015 - Present · University of Kansas School of Medicine

Credentials: · · · · · ·

History

2015 - Present Department · University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present

Hematology and Medical Oncology
University of Texas Health Science Center at San Antonio
2005–2008
Jordan University Hospital
2002–2005
Internal Medicine
Case Western Reserve University
1999–2002
Al Bashir Hospital
1998–1999
University of Jordan Faculty of Medicine
1994–1998

Research

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology · 2020 · 1,293 citations
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Journal of Clinical Oncology · 2020 · 909 citations
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Network Open · 2020 · 327 citations

Weijing Sun
17 papers
Anup Kasi
16 papers
Joaquina Baranda
14 papers
AS
Anwaar Saeed
12 papers
Stephen Williamson
8 papers
RP
Robin Park
4 papers · 4 as a resident
Azhar Saeed
3 papers · 3 as a resident
GA
Ghassan Abou-Alfa
3 papers
GV
Gina Vaccaro
3 papers
Mohammed Al-Jumayli
3 papers · 3 as a fellow
Rashna Madan
3 papers
AM
Adrian Murphy
2 papers

Clinical trials

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Principal investigator · Active not recruiting · Phase 1, Phase 2
University of Kansas Medical Center
2022–2026
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2026
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027